Ocular Therapeutix Sees Unusually High Options Volume (NASDAQ:OCUL)

Ocular Therapeutix, Inc. (NASDAQ:OCUL) saw some unusual options trading activity on Monday. Stock traders purchased 7,643 call options on the company. This represents an increase of 1,707% compared to the typical daily volume of 423 call options.

Insider Buying and Selling at Ocular Therapeutix

In other Ocular Therapeutix news, insider Donald Notman sold 6,301 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $7.84, for a total value of $49,399.84. Following the transaction, the insider now directly owns 204,563 shares in the company, valued at approximately $1,603,773.92. This represents a 2.99 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Pravin Dugel sold 21,475 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. The trade was a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,895 shares of company stock worth $283,772. Corporate insiders own 3.50% of the company’s stock.

Institutional Trading of Ocular Therapeutix

Large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in Ocular Therapeutix in the fourth quarter valued at approximately $28,000. Atlas Capital Advisors Inc. acquired a new stake in Ocular Therapeutix in the fourth quarter valued at approximately $43,000. Mirae Asset Global Investments Co. Ltd. grew its position in Ocular Therapeutix by 22.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,639 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 1,015 shares in the last quarter. AlphaQuest LLC acquired a new stake in Ocular Therapeutix in the fourth quarter valued at approximately $53,000. Finally, Capital Performance Advisors LLP acquired a new stake in Ocular Therapeutix in the third quarter valued at approximately $70,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Trading Down 12.0 %

OCUL traded down $0.86 on Monday, reaching $6.29. 749,857 shares of the company’s stock were exchanged, compared to its average volume of 923,737. The company’s 50 day moving average is $7.89 and its 200-day moving average is $8.92. The company has a market cap of $988.11 million, a price-to-earnings ratio of -4.74 and a beta of 1.22. Ocular Therapeutix has a twelve month low of $4.06 and a twelve month high of $11.77. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. Equities analysts predict that Ocular Therapeutix will post -0.98 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.